RNXT Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RenovoRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$2.35 |
| 52 Week Low | US$0.53 |
| Beta | 0.99 |
| 11 Month Change | 19.61% |
| 3 Month Change | 22.67% |
| 1 Year Change | 83.36% |
| 33 Year Change | -81.44% |
| 5 Year Change | n/a |
| Change since IPO | -83.61% |
Recent News & Updates
Recent updates
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Oct 26
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
Mar 31Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Dec 16RenovoRx reports Q2 results
Aug 15Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
Aug 04RenovoRx names new finance CFO
Jul 19RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
Mar 16We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
Nov 30Shareholder Returns
| RNXT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.2% | -6.5% | -1.0% |
| 1Y | 83.4% | 14.6% | 30.3% |
Return vs Industry: RNXT exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: RNXT exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| RNXT volatility | |
|---|---|
| RNXT Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNXT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNXT's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 10 | Shaun Bagai | renovorx.com |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
RenovoRx, Inc. Fundamentals Summary
| RNXT fundamental statistics | |
|---|---|
| Market cap | US$26.63m |
| Earnings (TTM) | -US$9.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs RNXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNXT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.16m |
| Earnings | -US$9.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RNXT perform over the long term?
See historical performance and comparison